Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

Thistle and Reduced Alkaline Phosphatase Level

Doses used in studies

mg/day: 140 (median 140, IQR 140–140) — 1 study

Time to effect

Median: 3.7 months · IQR 10.9 weeks–4.9 months · Range 6 weeks–6 months — Reported in 2 of 2 studies

Safety in these studies

Overall tolerabilityReported
The medication was well-tolerated, with minimal reported side effects (P > 0.05).
from: The hepatorenal protective effects of silymarin in cancer patients receiving chemotherapy:

2 of 2 papersPopulation:

The hepatorenal protective effects of silymarin in cancer patients receiving chemotherapy: a randomized, placebo-controlled trial.
- 2024-09-04
- RCT · n = 100
- BMC complementary medicine and therapies 24(1)
- - Safoora Sadat Erfanian
  - Hourieh Ansari
  - Shaghayegh Haghjooy Javanmard
  - Zahra Amini
  - Ali Hajigholami
- PubMed: 39232773
- DOI: 10.1186/s12906-024-04627-7
4 Insights on
- Reduced Alkaline Phosphatase Level
- High evidence
- Large Human Trial
- Clinical
Silymarin showed significant effects on liver enzymes in the levels of ALP and bilirubin (P < 0.05)
Effect
Beneficial
Effect size
Small
Significant
Yes
Dose
140 mg daily
Long-term safety and efficacy of a highly purified plant-based nutraceutical for improving clinical parameters of liver function in healthy participants: a randomized, double-blind, placebo-controlled clinical trial.
- 2026-01-23
- Clinical Trial · n = 130
- Frontiers in nutrition 12
- - Ghanashyam Patel
  - Saumin Shah
  - Christopher R D'Adamo
- PubMed: 41659807
- DOI: 10.3389/fnut.2025.1721748
4 Insights on
- Reduced Alkaline Phosphatase Level
- High evidence
- Adults
Mean improvements in ALT, AST, ALP, and GGT were significantly greater with the nutraceutical product than placebo (p ≤ 0.001).
Effect
Beneficial
Effect size
Moderate
Significant
Yes